Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Mar;71(3):578–582. doi: 10.1038/bjc.1995.112

Cellular fibronectin in serum and plasma: a potential new tumour marker?

S Ylätupa 1, C Haglund 1, P Mertaniemi 1, E Vahtera 1, P Partanen 1
PMCID: PMC2033647  PMID: 7880741

Abstract

The concentration of cellular fibronectin (cFN) containing the extra domain A (EDA) was measured in 479 plasma and 300 serum samples from healthy blood donors by a competitive enzyme immunoassay (EIA). Serum and plasma samples contained low concentrations of EDAcFN. The mean concentration of EDAcFN was higher in plasma (2.46 mg l-1) than in serum (0.30 mg l-1). No significant differences between sexes or age groups were found. The EDAcFN concentrations were also measured in 120 patients with various malignancies. The mean values in serum were 4.28 mg l-1, 2.01 mg l-1 and 5.18 mg l-1 in patients with digestive tract malignancies, breast cancer and a group of miscellaneous cancers respectively. In plasma, the corresponding values were 12.26 mg l-1, 4.38 mg l-1 and 11.12 mg l-1 respectively. The serum EDAcFN concentration was higher than the 97.5th percentile level of healthy blood donors in 86% of patients with digestive tract and in 76% with miscellaneous malignancies. In patients with breast cancer 60% had elevated levels of EDAcFN. The corresponding figures for plasma samples in patients with digestive tract and miscellaneous malignancies were 79% and 71% respectively. In patients with breast cancer only 30% had elevated plasma levels of EDAcFN. The mean values in serum and plasma of 20 patients with benign diseases were below the cut-off levels. Consistent with the EIA results, Western blotting revealed increased amounts of EDAcFN in blood samples from cancer patients. Pregnancy did not affect the EDAcFN concentration. The mean values in 20 pregnant women were below the cut-off levels.

Full text

PDF
578

Images in this article

581Figure 4
on p.581

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boccardo F., Guarneri D., Zanardi S., Castellani P., Borsi L., Zardi L. Fibronectin concentration in the plasma of patients with malignant and benign breast disease. Cancer Lett. 1986 Dec;33(3):317–323. doi: 10.1016/0304-3835(86)90071-6. [DOI] [PubMed] [Google Scholar]
  2. Bruhn H. D., Heimburger N. Factor-VIII-related antigen and cold-insoluble globulin in leukemias and carcinomas. Haemostasis. 1976;5(3):189–192. doi: 10.1159/000214134. [DOI] [PubMed] [Google Scholar]
  3. Choate J. J., Mosher D. F. Fibronectin concentration in plasma of patients with breast cancer, colon cancer, and acute leukemia. Cancer. 1983 Mar 15;51(6):1142–1147. doi: 10.1002/1097-0142(19830315)51:6<1142::aid-cncr2820510628>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  4. Eiján A. M., Puricelli L., Bal de Kier Joffé E., Entin D., Vuoto D., Orlando E., Sacerdote de Lustig E. Serial analysis of fibronectin concentration in plasma of patients with benign and malignant breast diseases. Cancer. 1986 Apr 1;57(7):1345–1349. doi: 10.1002/1097-0142(19860401)57:7<1345::aid-cncr2820570717>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  5. Engvall E., Ruoslahti E., Miller E. J. Affinity of fibronectin to collagens of different genetic types and to fibrinogen. J Exp Med. 1978 Jun 1;147(6):1584–1595. doi: 10.1084/jem.147.6.1584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fairbanks G., Steck T. L., Wallach D. F. Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry. 1971 Jun 22;10(13):2606–2617. doi: 10.1021/bi00789a030. [DOI] [PubMed] [Google Scholar]
  7. Fyrand O., Solum N. L. Studies on cold insoluble globulin in dermatological patients. I. Immunochemical quantitation in citrated plasma from patients with increased amounts of heparin precipitable fraction (HPF). Thromb Res. 1976 Nov;9(5):447–455. doi: 10.1016/0049-3848(76)90200-0. [DOI] [PubMed] [Google Scholar]
  8. Gould V. E., Koukoulis G. K., Virtanen I. Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Differ Dev. 1990 Dec 2;32(3):409–416. doi: 10.1016/0922-3371(90)90057-4. [DOI] [PubMed] [Google Scholar]
  9. Katayama M., Hino F., Kamihagi K., Sekiguchi K., Titani K., Kato I. Urinary fibronectin fragments (a potential tumor marker) measured by immunoenzymometric assay with domain-specific monoclonal antibodies. Clin Chem. 1991 Mar;37(3):466–471. [PubMed] [Google Scholar]
  10. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  11. Laitinen L., Vartio T., Virtanen I. Cellular fibronectins are differentially expressed in human fetal and adult kidney. Lab Invest. 1991 Apr;64(4):492–498. [PubMed] [Google Scholar]
  12. Lockwood C. J., Senyei A. E., Dische M. R., Casal D., Shah K. D., Thung S. N., Jones L., Deligdisch L., Garite T. J. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med. 1991 Sep 5;325(10):669–674. doi: 10.1056/NEJM199109053251001. [DOI] [PubMed] [Google Scholar]
  13. Mosher D. F. Fibronectin. Prog Hemost Thromb. 1980;5:111–151. [PubMed] [Google Scholar]
  14. Mosher D. F., Williams E. M. Fibronectin concentration is decreased in plasma of severely ill patients with disseminated intravascular coagulation. J Lab Clin Med. 1978 May;91(5):729–735. [PubMed] [Google Scholar]
  15. Parsons R. G., Todd H. D., Kowal R. Isolation and identification of a human serum fibronectin-like protein elevated during malignant disease. Cancer Res. 1979 Nov;39(11):4341–4345. [PubMed] [Google Scholar]
  16. Peters J. H., Ginsberg M. H., Case C. M., Cochrane C. G. Release of soluble fibronectin containing an extra type III domain (ED1) during acute pulmonary injury mediated by oxidants or leukocytes in vivo. Am Rev Respir Dis. 1988 Jul;138(1):167–174. doi: 10.1164/ajrccm/138.1.167. [DOI] [PubMed] [Google Scholar]
  17. Peters J. H., Maunder R. J., Woolf A. D., Cochrane C. G., Ginsberg M. H. Elevated plasma levels of ED1+ ("cellular") fibronectin in patients with vascular injury. J Lab Clin Med. 1989 May;113(5):586–597. [PubMed] [Google Scholar]
  18. Ruelland A., Kerbrat P., Clerc C., Legras B., Cloarec L. Level of plasma fibronectin in patients with breast cancer. Clin Chim Acta. 1988 Dec 30;178(3):283–287. doi: 10.1016/0009-8981(88)90236-7. [DOI] [PubMed] [Google Scholar]
  19. Schwarzbauer J. E. Fibronectin: from gene to protein. Curr Opin Cell Biol. 1991 Oct;3(5):786–791. doi: 10.1016/0955-0674(91)90051-y. [DOI] [PubMed] [Google Scholar]
  20. Stathakis N. E., Fountas A., Tsianos E. Plasma fibronectin in normal subjects and in various disease states. J Clin Pathol. 1981 May;34(5):504–508. doi: 10.1136/jcp.34.5.504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tamkun J. W., Hynes R. O. Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem. 1983 Apr 10;258(7):4641–4647. [PubMed] [Google Scholar]
  22. Todd H. D., Coffee M. S., Waalkes T. P., Abeloff M. D., Parsons R. G. Serum levels of fibronectin and a fibronectin-like DNA-binding protein in patients with various diseases. J Natl Cancer Inst. 1980 Nov;65(5):901–904. [PubMed] [Google Scholar]
  23. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Vartio T., Laitinen L., Närvänen O., Cutolo M., Thornell L. E., Zardi L., Virtanen I. Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. J Cell Sci. 1987 Nov;88(Pt 4):419–430. doi: 10.1242/jcs.88.4.419. [DOI] [PubMed] [Google Scholar]
  25. Virtanen I., Laitinen L., Vartio T. Differential expression of the extra domain-containing form of cellular fibronectin in human placentas at different stages of maturation. Histochemistry. 1988;90(1):25–30. doi: 10.1007/BF00495702. [DOI] [PubMed] [Google Scholar]
  26. Webb K. S., Lin G. H. Urinary fibronectin: potential as a biomarker in prostatic cancer. Invest Urol. 1980 Mar;17(5):401–404. [PubMed] [Google Scholar]
  27. Ylätupa S., Partanen P., Haglund C., Virtanen I. Competitive enzyme immunoassay for quantification of the cellular form of fibronectin (EDAcFN) in blood samples. J Immunol Methods. 1993 Jul 6;163(1):41–47. doi: 10.1016/0022-1759(93)90237-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES